![logo](/logos/BEAM.webp)
Beam Therapeutics Inc.
NASDAQ:BEAM
23.31 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Beam Therapeutics Inc. |
Symbool | BEAM |
Munteenheid | USD |
Prijs | 23.31 |
Beurswaarde | 1,921,107,636 |
Dividendpercentage | 0% |
52-weken bereik | 16.95 - 49.5 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. John M. Evans M.B.A. |
Website | https://www.beamtx.com |
An error occurred while fetching data.
Over Beam Therapeutics Inc.
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)